NINLARO® is the commercial brand name of Ixazomib Citrate Capsules, an orally active, reversible proteasome inhibitor developed by Takeda Pharmaceuticals. It exerts anti-tumor activity by inhibiting the chymotrypsin-like activity of the 20S proteasome, thereby disrupting the ubiquitin-proteasome pathway, inducing endoplasmic…
Retsevmo® is the commercial brand name of Selpercatinib Capsules, an orally active, highly selective rearranged during transfection (RET) inhibitor developed by Eli Lilly and Innovent Biologics. It exerts anti-tumor activity by specifically inhibiting the kinase activity of RET, thereby blocking…
SUTENT® is the commercial brand name of Sunitinib Malate Capsules, an orally active, multi-targeted tyrosine kinase inhibitor (TKI) developed by Pfizer. It exerts anti-tumor activity by inhibiting multiple receptor tyrosine kinases, including VEGFR, PDGFR, KIT, FLT3, and RET, thereby suppressing…
AUGTYRO® is the commercial brand name of Repotrectinib Capsules, a next-generation, orally active, highly selective dual inhibitor of tropomyosin receptor kinase (TRK) and rearranged during transfection (RET) developed by Bristol Myers Squibb. It exerts anti-tumor activity by potently inhibiting the…
GAVRETO® is the commercial brand name of Pralsetinib Capsules, an orally active, highly selective rearranged during transfection (RET) inhibitor developed by Blueprint Medicines and licensed to BeiGene. It exerts anti-tumor activity by specifically inhibiting the kinase activity of RET, thereby…
VITRAKVI® is the commercial brand name of Larotrectinib Sulfate Capsules, a highly selective tropomyosin receptor kinase (TRK) inhibitor developed by Bayer. It exerts anti-tumor activity by specifically inhibiting the kinase activity of tropomyosin receptor kinases (TRKA, TRKB, TRKC) encoded by…
LENVIMA® is the commercial brand name of Lenvatinib Mesilate Capsules, an orally active, multi-targeted tyrosine kinase inhibitor (TKI) developed by Eisai. It exerts anti-tumor activity by inhibiting multiple receptor tyrosine kinases, including VEGFR, FGFR, PDGFR, RET, and KIT, thereby suppressing…
Rozlytrek® is the commercial brand name of Entrectinib Capsules, an orally active, highly selective tropomyosin receptor kinase (TRK) and ROS1 inhibitor developed by Roche. It exerts anti-tumor activity by inhibiting the kinase activity of TRK and ROS1, thereby blocking downstream…
CALQUENCE® is the commercial brand name of Acalabrutinib Capsules, a highly selective, irreversible second-generation Bruton tyrosine kinase (BTK) inhibitor developed by AstraZeneca. It exerts anti-tumor activity by covalently binding to BTK, thereby inhibiting B-cell receptor signaling and blocking the proliferation…
IBRANCE® is the commercial brand name of Palbociclib Capsules, a first-in-class, orally active cyclin-dependent kinase 4/6 (CDK4/6) inhibitor developed by Pfizer. It exerts anti-tumor activity by selectively inhibiting CDK4/6, thereby blocking the phosphorylation of the retinoblastoma (Rb) protein, arresting the…